jilibet super ace
Nontuberculous Mycobacterial Infections Treatment Market Size was ~USD 360 Million in the US in 2023, is expected to grow by 2034 | DelveInsight 12-19-2024 11:22 PM CET | Health & Medicine Press release from: ABNewswire DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States. Explore the intricate details of the Nontuberculous Mycobacterial Infections Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Nontuberculous Mycobacterial Infections Market Forecast. Click here to stay ahead in healthcare innovation @ Nontuberculous Mycobacterial Infections Market Size [ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Key Takeaways from the Non-Tuberculous Mycobacterial Infections Market Report * The Non-Tuberculous Mycobacterial Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034) * Based on DelveInsight's epidemiology model, the total number of diagnosed prevalent cases of Nontuberculous Mycobacterial Infections in the US was around 108,000 in 2023, with an anticipated increase during the forecast period (2024-2034) due to various contributing factors. * In 2023, NTM Infections in the US showed a higher prevalence in females compared to males. Females represented about 68% of the total diagnosed prevalent cases of Nontuberculous Mycobacterial Infections, while males accounted for around 32%. * In 2023, M. avium was the most common species responsible for Nontuberculous Mycobacterial Infections in the US, accounting for nearly 76 thousand diagnosed prevalent cases. It was followed by M. abscessus with around 14 thousand cases, and other species like M. kansasii and M. xenopi, which contributed to approximately 18 thousand cases. * In 2023, the US had about 86 thousand diagnosed prevalent cases of Nontuberculous Mycobacterial Infections of the pulmonary type and approximately 22 thousand cases of the extrapulmonary type * As per Shanmugam et al., about 15 million people died from TB, and nearly 10 million people fall ill with Mtb infection worldwide, of which only 64 million were diagnosed and officially reported * Among the 7MM countries. The most prevalent cases of Non- Tuberculous Mycobacterial infections were recorded in the United States. * The leading Non- Tuberculous Mycobacterial Infections Companies such as Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune , and others * Promising Non- Tuberculous Mycobacterial Infections Therapies such as SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107 , and others Navigate the complexities of the Nontuberculous Mycobacterial Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Nontuberculous Mycobacterial Infections Market Forecast. Click here to get more insights @ Nontuberculous Mycobacterial Infections Treatment Market [ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Non-Tuberculous Mycobacterial Infections Epidemiology Segmentation in the 7MM * Total Prevalence of Non- Tuberculous Mycobacterial Infections * Prevalent Cases of Non- Tuberculous Mycobacterial Infections by severity * Gender-specific Prevalence of Non- Tuberculous Mycobacterial Infections * Diagnosed Cases of Episodic and Chronic Non- Tuberculous Mycobacterial Infections Download the report to understand which factors are driving Non-Tuberculous Mycobacterial Infections epidemiology trends @ Non-Tuberculous Mycobacterial Infections Prevalence [ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Nontuberculous Mycobacterial Infections Marketed Drugs * ARIKAYCE (amikacin liposome inhalation suspension): Insmed ARIKAYCE is the first FDA-approved therapy indicated for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where lung macrophages take it up, targeting the site of infection. This approach prolongs the release of amikacin in the lungs while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira Nebulizer System manufactured by PARI Pharma GmbH. Nontuberculous Mycobacterial Infections Emerging Drugs * Epetraborole: AN2 Therapeutics Epetraborole (EBO), developed by AN2 Therapeutics, is a novel, once-daily, orally administered investigational treatment for patients with chronic NTM lung disease. Epetraborole is a boron-containing small molecule inhibitor of bacterial leucyl-tRNA synthetase, or LeuRS, an enzyme that catalyzes the attachment of leucine to transfer RNA, or tRNA, molecules, an essential step in protein synthesis. Epetraborole forms a complex with a tRNALEU molecule, trapping the terminal ribonucleotide of tRNALEU in the editing site of the enzyme, which prevents the synthetic site from attaching leucine to tRNALEU thus shutting down tRNA leucylation and leading to a block in protein synthesis. Currently, the drug is in Phase II/III of clinical development for the treatment of patients with NTM lung disease. AN2 Therapeutics intends to expand the indication targeted by epetraborole by pursuing development in other mycobacterial diseases, including treatment-naive MAC lung disease. AN2 Therapeutics also intends to conduct trials in which they plan to incorporate epetraborole as part of first-line combination treatment for treatment-naive patients with NTM lung disease and M. abscessus lung infections. * MNKD-101 (Clofazimine Inhalation Suspension): Mannkind Corporation MNKD-101, a nebulized formulation of clofazimine, is being developed for the treatment of severe chronic and recurrent pulmonary infections, including NTM lung disease. An orally inhaled formulation of clofazimine is anticipated to offer several clinical advantages over the current solid oral dosage form of this drug. MNKD-101 has been designated as both an orphan drug and a qualified infectious disease product by the US FDA for the treatment of pulmonary NTM infections. Mannkind is also assessing the feasibility of developing a dry-powder formulation of clofazimine using Mannkind's technosphere formulation technology. MNKD-101 is designated with fast-track designation by the US FDA for the treatment of NTM lung infections. Mannkind intends to commence a Phase III registration study of MNKD-101 in the US in the second quarter of 2024. * SPR720 (Fobrepodacin): Spero Therapeutics SPR720, developed by Spero Therapeutics, is a broad-spectrum oral antibiotic designed to treat NTM pulmonary disease. SPR720 employs a novel mechanism and has no known cross-resistance with marketed antibiotics. SPR720 has demonstrated a broad spectrum of activity in preclinical studies against the most common organisms causing NTM infections, including M. avium complex, or MAC, M. kansasii, and M. abscessus. SPR720 is applicable to both nonrefractory and refractory patients. Unlock insights into the Nontuberculous Mycobacterial Infections Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Nontuberculous Mycobacterial Infections Market Forecast. Click here @ Nontuberculous Mycobacterial Infections Market Drivers and Barriers [ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Non- Tuberculous Mycobacterial Infections Therapies and Companies * SPR720: Spero Therapeutics * Molgramostim: Savara Pharmaceuticals * Thiolanox (Nitric Oxide): Mallinckrodt Inc. * NUZYRA (omadacycline): Paratek Pharmaceuticals Inc. * CYT 107: Revimmune Scope of the Non- Tuberculous Mycobacterial Infections Market Report * Study Period: 2020-2034 * Coverage: 7MM * Non-Tuberculous Mycobacterial Infections Companies: Spero Therapeutics, Savara Pharmaceuticals, Mallinckrodt Inc., Paratek Pharmaceuticals Inc., Revimmune, and others * Non-Tuberculous Mycobacterial Infections Therapies: SPR720, Molgramostim, Thiolanox (Nitric Oxide), NUZYRA (omadacycline), CYT 107, and others * Non-Tuberculous Mycobacterial Infections Therapeutic Assessment: Non- Tuberculous Mycobacterial Infections current marketed and Non- Tuberculous Mycobacterial Infections emerging therapies * Non-Tuberculous Mycobacterial Infections Market Dynamics: Non- Tuberculous Mycobacterial Infections market drivers and Non- Tuberculous Mycobacterial Infections market barriers * Non- Tuberculous Mycobacterial Infections Unmet Needs, KOL's views, Analyst's views, Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement Gain a strategic edge in the Nontuberculous Mycobacterial Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Nontuberculous Mycobacterial Infections Market Forecast. Click here to lead in advancements @ Nontuberculous Mycobacterial Infections Clinical Trials Assessment [ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr ] Table of Contents 1. Non- Tuberculous Mycobacterial Infections Market Report Introduction 2. Executive Summary for Non- Tuberculous Mycobacterial Infections 3. SWOT analysis of Non- Tuberculous Mycobacterial Infections 4. Non- Tuberculous Mycobacterial Infections Patient Share (%) Overview at a Glance 5. Non- Tuberculous Mycobacterial Infections Market Overview at a Glance 6. Non- Tuberculous Mycobacterial Infections Disease Background and Overview 7. Non- Tuberculous Mycobacterial Infections Epidemiology and Patient Population 8. Country-Specific Patient Population of Non- Tuberculous Mycobacterial Infections 9. Non- Tuberculous Mycobacterial Infections Current Treatment and Medical Practices 10. Non- Tuberculous Mycobacterial Infections Unmet Needs 11. Non- Tuberculous Mycobacterial Infections Emerging Therapies 12. Non- Tuberculous Mycobacterial Infections Market Outlook 13. Country-Wise Non- Tuberculous Mycobacterial Infections Market Analysis (2020-2034) 14. Non- Tuberculous Mycobacterial Infections Market Access and Reimbursement of Therapies 15. Non- Tuberculous Mycobacterial Infections Market Drivers 16. Non- Tuberculous Mycobacterial Infections Market Barriers 17. Non- Tuberculous Mycobacterial Infections Appendix 18. Non- Tuberculous Mycobacterial Infections Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=nontuberculous-mycobacterial-infections-treatment-market-size-was-usd-360-million-in-the-us-in-2023-is-expected-to-grow-by-2034-delveinsight ] Phone: 09650213330 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage This release was published on openPR.Overall, Marvel's Vanguard is a standout title in the realm of superhero games, offering a compelling narrative, stunning visuals, and engaging gameplay that sets it apart from the competition. With its 8/10 rating from IGN, the game has solidified its position as a top contender for the crown among similar games in the genre.But the success of Mr. Li's venture goes beyond mere financial gains. By repurposing wood waste and straw into valuable crops, he has set an example of how sustainable practices can lead to prosperity. The once-discarded materials are now seen as valuable resources, demonstrating the transformative power of innovation and forward thinking.The ceremony at Rodney Parade will celebrate the health and care providers across South Wales, and the finalists have been revealed. Arian Care believes that happy, well supported and valued staff provide the best possible standard of care and support to individuals so therefore invests heavily in its staff team. Among things it does are: above average rates of pay and mileage; supportive office team, open door policy, regular meetings and social opportunities provided; snacks, drinks always available for staff ( and their children) when they visit the office; box of toys and activities for children that visit the office with their parent - this is to support Arian Care's vision of being a family focused employer; period, menopause and andropause positive employer that supply's sanitary products to all staff available from the office. St David's Hospice Care employs just over 200 staff and every single person is important and contributes to the over all success of the hospice. It is a fair and equal employer which supports staff in many ways. A menopause support group has been established, a number of mental health first-aiders have been trained to support staff and an annual well-being survey is undertaken to 'check in' with staff to see how they are feeling about work, life and everything. Their comments and thoughts are requested to see where things can be improved and what needs to be done differently. The CEO sends out a monthly briefing to all staff to ensure everyone is aware of what is going on and any news across the hospice. Aneurin Bevan University Health Board in Monmouthshire and Monmouthshire County Council believe the working environment is the best place to work due to the integration and innovative ideas continually produced. Both organisations endeavour to treat all employees with respect and equality through all levels of staffing and look at how to improve and if wanted progress careers. Both organisations encourage employees to take pride in their work, often with successes being shared on the intranet, via email, Good News items on agendas, and included in newsletters.
By WYATTE GRANTHAM-PHILIPS NEW YORK (AP) — A ransomware attack that hit a major software provider last week caused disruptions for a handful of companies over recent days, from Starbucks to U.K. grocery giant Morrisons. Blue Yonder, which provides supply chain technology to a range of brands worldwide, said that it experienced disruptions to services it manages for customers on Thursday, which the third-party software supplier determined to be “the result of a ransomware incident.” Some systems went offline, impacting clients using Blue Yonder’s software. A spokesperson for Starbucks, for example, said that the chain’s ability to manage barista schedules and track hours was disrupted — meaning store leaders across North America are currently being instructed to use manual workarounds. Starbucks maintained that the outage is not impacting how customers are served and that ensuring workers get paid for all hours worked is a top priority. While the company continues to work towards full recovery, the spokesperson added that Starbucks was able to process payroll again as of Tuesday morning. Two of the U.K.’s biggest grocers, Morrisons and Sainsbury’s, were also affected — with both telling CNN over the weekend that they had turned to contingency plans to keep operations flowing. A spokesperson for Morrisons confirmed to The Associated Press that the outage “impacted our warehouse management systems for fresh and produce” and that it was continuing to operate on back up systems Tuesday. Sainsbury’s, meanwhile, said Tuesday that its service was restored. Blue Yonder declined to disclose how many of its customers were impacted by the hack. In a statement sent to the AP, a spokesperson maintained that it had notified “relevant customers” and would continue to communicate as needed. The spokesperson also maintained that recovery efforts were still underway — noting that Blue Yonder “has been working diligently together with external cybersecurity firms to make progress,” including the implementation of several defensive and forensic protocols. Blue Yonder’s website touts an extensive global roster of customers — including Gap, Ford and Walgreens. Walgreens and Gap were not impacted following the ransomware attack, spokespeople for the companies said. Ford shared that it was investigating whether the incident affected its operations earlier this week, but had no further updates when reached Tuesday. Blue Yonder, based in Arizona, is a subsidiary of Japan’s Panasonic Corp. Panasonic acquired the supply chain software firm in September 2021.
- Previous: jilimacao super ace
- Next: jili games super ace
